New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:44 EDTMGNXMacroGenics reports milestone in DART program triggers $20M in payments
MacroGenics announced that Servier, France's largest privately-held pharmaceutical company, has exercised its exclusive option to develop and commercialize MGD006, a DART-based product candidate developed by MacroGenics. Servier will gain exclusive development and commercial rights in all countries outside of the U.S., Canada, Mexico, Japan, South Korea and India. In those countries, MacroGenics will retain development and commercialization rights. As a result of the exercise, MacroGenics will receive a $15M payment from Servier. In addition, the Investigational New Drug application for MGD006 has cleared the 30 day review period by the U.S. Food and Drug Administration, triggering an additional $5M payment to MacroGenics by Servier.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
17:26 EDTMGNXMacroGenics to present Phase 1 margetuximab study data at ASCO
MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that clinical data from its Phase 1 study of margetuximab will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology, ASCO, which is being held from May 29 to June 2 in Chicago, Illinois.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use